Epsilogen

The world's leading pan-isotype therapeutic antibody company

Founded 2016 · $65.8M raised

Employees
11–50
Founded
2016
Business Model
B2B
Total Funding
$65.8M
Last Round
$17.0M Extension RoundSep 2024
Rounds
3

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Epsilogen is a clinical-stage company pioneering antibody therapeutics for oncology, with proprietary expertise in the discovery and development of IgE, IgA and IgG-based medicines. Evolved to treat parasitic infection, IgE can activate myeloid cells and T cells against tumours, while IgA acts through neutrophils; Epsilogen matches isotype to cancer type. Its lead candidate, MOv18 IgE, targets folate receptor alpha, completed a phase I trial in ovarian cancer, and is in a phase Ib study in platinum-resistant ovarian cancer. The company has also built platforms for bispecific IgE and IgEG antibodies.

Summary

Epsilogen is a Biotech company, founded in 2016. It has raised $65.8M in total across 3 rounds, most recently a $17.0M Extension Round in Sep 2024. Investors include Novartis Venture Fund, Epidarex Capital and British Patient Capital.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Extension RoundSeries B ExpansionSep 2024
$17.0M

Sign up to see all 3 events

Funding: Series A through Extension Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Epsilogen on Indexed.vc
<a href="https://indexed.vc/companies/epsilogen"><img src="https://indexed.vc/api/badge/company/epsilogen" alt="Epsilogen on Indexed.vc" width="260" height="76" /></a>